Clinical Trials Directory

Trials / Not Yet Recruiting

Not Yet RecruitingNCT06751888

Controlled CO2 Inhalation in NOH

Controlled CO2 Inhalation to Increase Blood Pressure in Neurogenic Orthostatic Hypotension: a Proof-of-Concept Novel Therapy Study

Status
Not Yet Recruiting
Phase
N/A
Study type
Interventional
Enrollment
28 (estimated)
Sponsor
University of Calgary · Academic / Other
Sex
All
Age
18 Years
Healthy volunteers
Not accepted

Summary

This study focuses on neurogenic orthostatic hypotension (nOH), which is a disorder characterized by an abnormal drop in blood pressure (BP) within 3-minutes of standing. Patients with nOH experience debilitating symptoms including light-headedness, falls, and fainting. Patients often struggle with day-to-day tasks that require standing, with a reduced quality-of-life. Current therapies for nOH have limited effectiveness and unwanted side effects. Our lab has found that raising blood CO2 levels (hypercapnia) in the lab increases BP when standing in patients with nOH. We now aim to test the CarboHaler, an exogenous controlled CO2 delivery device, in this study to see if increasing CO2 levels through controlled CO2 inhalation can improve BP and reduce symptoms in patients with nOH when standing up. On the study day, participants will undergo two Head-up Tilt (HUT; upright) tests with different breathing protocols: one with and one without exogenous CO2 delivery provided by a CO2 inhalational device. We will record heart rate, blood pressure, and breathing parameters. We will also assess upright symptoms using the Vanderbilt Orthostatic Symptoms Score. Our primary outcome is the magnitude of the change in systolic BP from lying down to standing, which will be compared with and without exogenous CO2 delivery. We hypothesize that exogenous CO2 delivery provided by a CO2 inhalational device will raise CO2 enough to increase standing BP, which could reduce the debilitating symptoms experienced by patients with nOH. We hope that these data will support future clinical trials, with the long-term goal of creating a simple, low-cost treatment for increasing quality-of-life for patients with nOH.

Conditions

Interventions

TypeNameDescription
OTHERControlled CO2 deliveryThe use of a controlled CO2 delivery offers a straightforward way to increase arterial CO2. Controlled CO2 inhalation may offer a novel hemodynamic therapy for patients with Neurogenic Orthostatic Hypotension
DEVICEControlled CO2 delivery (Sham)For this intervention, we will be using this device set at 0% CO2 for our sham comparison.

Timeline

Start date
2025-05-01
Primary completion
2028-12-31
Completion
2028-12-31
First posted
2024-12-30
Last updated
2024-12-30

Locations

1 site across 1 country: Canada

Source: ClinicalTrials.gov record NCT06751888. Inclusion in this directory is not an endorsement.